To advance the possibility of off-the-shelf cardiac cell therapies, scientists devise an engineered cardiac stem cell that avoids stimulating a detrimental immune attack.

Dropping the transcription factor from the four so-called Yamanaka factors reduces the efficiency of inducing the production of stem cells, but the resulting cells are of greater quality.

The patient’s vision has improved since the procedure, and her cornea remains clear.

The cells, derived from induced pluripotent stem cells, are in testing as an immunotherapy for cancer patients with solid tumors.

Many researchers see the move to relax the rules as a welcome change, yet some are worried the revisions don’t take public concerns enough into consideration.

Uncertainties about the cells’ risk profiles and the potential for hyping unproven therapies mean scientists and the media must tread carefully.

The treatment will be tested in a handful of patients who suffered nerve damage in sports or traffic accidents.

From disastrous scientific setbacks to the upending of scientific dogma and the end of a 40-year search for a protein